7 years after launch, Sanofi’s Dupixent is set for a megablockbuster run

French drugmaker Sanofi has been playing the long game when it comes to the blockbuster Dupixent, and the results are starting to show. First approved for atopic dermatitis in 2017, the skin and asthma immunology medicine that inhibits interleukin 4 and interleukin 13 brought in record sales in the second quarter this year and has some big potential approvals on the horizon.